Esperion Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ESPR Nasdaq 2836 www.esperion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Esperion Therapeutics, Inc.

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - Jan 11th, 2026 4:00 pm
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference - Jan 5th, 2026 6:00 am
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes - Dec 19th, 2025 6:00 am
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results - Dec 9th, 2025 5:12 pm
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Dec 9th, 2025 2:30 pm
Why Analysts Are Rewriting Esperion’s Story After New Pipeline Results and Global Partnerships - Nov 25th, 2025 7:11 am
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia - Nov 21st, 2025 6:00 am
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference - Nov 19th, 2025 6:00 am
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease - Nov 18th, 2025 5:00 am
HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease - Nov 18th, 2025 5:00 am
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025 - Nov 10th, 2025 6:00 am
Tracking the Narrative for Esperion Therapeutics as Analyst Optimism Grows Amid Shifting Fundamentals - Nov 9th, 2025 10:08 am
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down - Nov 7th, 2025 9:22 am
Esperion Therapeutics Inc (ESPR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Nov 6th, 2025 12:06 pm
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates - Nov 6th, 2025 5:10 am
Esperion Therapeutics: Q3 Earnings Snapshot - Nov 6th, 2025 4:11 am
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 6th, 2025 4:00 am
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer - Nov 4th, 2025 6:00 am
Esperion to Participate in Jefferies Global Healthcare Conference - London - Nov 3rd, 2025 6:00 am
GS1 Hong Kong Equips Local Businesses to Turn EU's Digital Product Passport Mandate into a Competitive Edge - Oct 31st, 2025 2:03 am